No Data
No Data
Hong Kong stocks unusual movement | cms (01681) rose nearly 8% in early trading, Lucentin cream is expected to fill the gap in the domestic vitiligo market, the impact of centralized procurement has been basically cleared
cms (01681) rose nearly 8% in early trading, as of the press release, up 6.39%, at 8.16 Hong Kong dollars, with a turnover of 38.5871 million Hong Kong dollars.
Consun Pharmaceutical Group (HKG:1681) Jumps 8.3% This Week, Though Earnings Growth Is Still Tracking Behind Three-year Shareholder Returns
康臣葯業:2024 中期報告
Insiders of Consun Pharmaceutical Group Limited (HKG:1681) Have Had a Great Week After Last Week's HK$446m Gain and They Haven't Stopped Buying
Consun Pharma (01681.HK) has received an increase in shareholding of 0.295 million shares by Executive Director and Chairman An Meng.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on September 17, 2024, Consun Pharma (01681.HK) was disclosed to have received 0.295 million shares at an average price of 5.80 Hong Kong dollars per share by the executive director and chairman An Meng on September 13, 2024. The total amount involved is approximately 1.711 million Hong Kong dollars. After the shareholding, the latest number of shares held is 219,527,000 shares, increasing the shareholding percentage from 25.95% to 25.98%.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
No Data
No Data